Zydus Cadila, Ahmedabad based drug firm, to initiate Phase III clinical trials of its Covid-19 vaccine ZyCoV-D. The move came after DGCI approved Serum Institute of India's Covishield and Bharat Biotech's COVAXIN for emergency use.Also Read | A year on, China is shaking up the world"The nation's first indigenously developed DNA vaccine candidate against COVID-19, ZyCoV-D, by M/s Zydus Cadila has been approved by Drugs Controller General of India (DCGI), for the conduct of the Phase III clinical trials," the Ministry of Science and Technology said in a release on Sunday..@DBTIndia-@BIRAC_2012 supported indigenously developed DNA Vaccine Candidate by @ZydusUniverse, approved for Phase III clinical trials by Drugs Controller General of.